The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases
Open Access
- 1 February 2003
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (7) , 4847-4853
- https://doi.org/10.1074/jbc.m209321200
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast CellsJournal of Investigative Dermatology, 2000
- Association of Lyn tyrosine kinase to the GM-CSF and IL-3 receptor common βc subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosisGenes to Cells, 2000
- Recent Advances in Mastocytosis ResearchInternational Archives of Allergy and Immunology, 1999
- CHK Down-Regulates SCF/KL-Activated Lyn Kinase Activity in Mo7e Megakaryocytic CellsBiochemical and Biophysical Research Communications, 1999
- Gain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal TumorsScience, 1998
- BCR – ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent mannerOncogene, 1998
- Src family‐selective tyrosine kinase inhibitor, PP1, inhibits both FcεRI‐ and Thy‐1‐mediated activation of rat basophilic leukemia cellsEuropean Journal of Immunology, 1997
- Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase InhibitorJournal of Biological Chemistry, 1996
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.Journal of Clinical Investigation, 1993
- Selective growth response to IL‐3 of a human leukaemic cell line with megakaryoblastic featuresBritish Journal of Haematology, 1988